Structure Therapeutics Inc. American Depositary Shares

Structure Therapeutics has priced a public offering of 8,461,538 American depositary shares at $65.00 per share and pre-funded warrants to purchase 1,538,462 ADSs, expecting to raise approximately $650 million.

Structure Therapeutics is developing an oral weight-management drug called aleniglipron, targeting the hot obesity treatment market. The company's success depends on strong clinical trial results, with potential for significant stock price movement based on its phase 2 study outcomes.

Pfizer's challenging period may be turning around with strong Q1 performance and potential changes under new leadership. Learn more about PFE stock's buy rating.

Structure Therapeutics (GPCR) stock sees an upside on positive top-line data from a phase IIa obesity study as well as a capsule-to-tablet PK study on its obesity candidate, GSBR-1290.

On Monday, Structure Therapeutics Inc. (NASDAQ:GPCR) revealed 12-week topline obesity data from its Phase 2a study of GSBR-1290. In the Phase 2a obesity study, GSBR-1290 demonstrated a clinically meaningful and statistically significant placebo-adjusted mean decrease in weight of 6.2% at 12 weeks. Cantor Fitzgerald maintains its bullish views o...